GB2029216A - Compositions containing xanthan gum - Google Patents

Compositions containing xanthan gum Download PDF

Info

Publication number
GB2029216A
GB2029216A GB7922348A GB7922348A GB2029216A GB 2029216 A GB2029216 A GB 2029216A GB 7922348 A GB7922348 A GB 7922348A GB 7922348 A GB7922348 A GB 7922348A GB 2029216 A GB2029216 A GB 2029216A
Authority
GB
United Kingdom
Prior art keywords
xanthan gum
appetite suppressant
suppressant composition
appetite
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
GB7922348A
Other versions
GB2029216B (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Catalent UK Swindon Encaps Ltd
Original Assignee
Catalent UK Swindon Encaps Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Catalent UK Swindon Encaps Ltd filed Critical Catalent UK Swindon Encaps Ltd
Publication of GB2029216A publication Critical patent/GB2029216A/en
Application granted granted Critical
Publication of GB2029216B publication Critical patent/GB2029216B/en
Expired legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21Addition of substantially indigestible substances, e.g. dietary fibres
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Medicinal Preparation (AREA)

Abstract

An appetite suppressant composition comprises xanthan gum in association with an orally acceptable carrier or diluent. The composition is suitably in dosage unit form such as tablet form, wafer or biscuit form, or, especially, in the form of a solution or dispersion of xanthan gum contained in a gelatine capsule.

Description

SPECIFICATION Appetite suppressant compositions This invention relates to materials which are adapted to suppress the appetite. Various chemical appetite suppressants are already known. One form of appetite suppressant is methyl cellulose or derivatives thereof which acts by increasing the viscosity of the gastric juices and thereby delays gastric transfer.
There has now been found, in accordance with the present invention, a material which has not previously been used or suggested for appetite suppressant compositions and which is active in far smaller quantities than methyl cellulose or its derivatives.
The present invention therefore provides appetite suppressant compositions and a method of appetite suppression.
In accordance with the invention the active material used in the composition and method is Xanthan Gum. Xanthan Gum is described in the United States National Formulary XIV as "a high molecular weight polysaccharide gum produced by a pureculture fermentation of a carbohydrate with Xanthomonas campestris then purified by recovery with isopropyl alcohol, dired and milled. It contains D-glucose and D-mannose as the dominant hexose units, along with D-glucuronic acid, and is prepared as the sodium, potassium or calcium salt. It yields not less than 4.2 percent and not more than 5.0 percent of carbon dioxide, calculated on the dried basis, corresponding to not less than 91.0 percent and not more than 108.0 percent of Xanthan Gum.
It has been found that Xanthan Gum at low concentrations in gastric juices substantially increases the viscosity of such juices. Xanthan Gum has already been approved for food use as it has been found to have extremely lowtoxity. It has been found further to have extremely lowtoxicity. It has been found further that less than 100 mg per day when administered orally to human subjects is not effective as an appetite suppressant. There has not established any maximum quantity in which the material may be used as an appetite suppressant but the preferred daily dosage for use in accordance with the invention ranges from 500 mg to 3 grams.
Accordingly, one embodiment of the present invention provides an appetite suppressant composition comprising an orally acceptable xanthan gum in association with an orally acceptable carrier or diluent.
Xanthan gum may be used therapeutically to suppress the appetite of human beings, for example in the treatment of obesity and thus the invention also provides an orally acceptable therapeutic composition for suppressing the appetite of human beings comprising xanthan gum.
Xanthan gum may also be employed to suppress appetite in non-therapeutic applications, for example where a subject wishes to suppress weight for reasons other than purely medical reasons and thus the invention also provides a non-therapeutic method of suppressing the appetite of a human subject which comprises administering to the subject at least 100 mg of xanthan gum per day.
The Xanthan Gum may be formulated in accordance with the invention in any form suitable for oral administration. Such forms include tablets which may be chewed or swallowed with water or granules which may be mixed with water then swallowed.
The active material may alternatively be formulated into wafers or biscuits. The preferred form of formulation is that of capsules, preferably gelatine capsules, which dissolve in the gastric juices and to which other materials in addition to the active Xanthan Gum may be added as a vehicle and/for dietary or other reasons, for example vitamins.
It is convenient to formulate the xanthan gum in dosage unit form (i.e. in the form of orally acceptable units each containing a specified amount of xanthan gum) such as the tablets, wafers or biscuits, or capsules referred to above. In this latter case the xanthan gum will generally be provided as a solution or suspension thereof in a carrier or vehicle such as a vegetable oil, optionally with one or more suspending or emulsifying agents. Such dosage units may suitably contain from 100 to 3,000 mg of xanthan gum, preferable from 500 to 3,000 mg of xanthan gum.
A dosage form containing 500 mg of Xanthan Gum is preferred for convenient dosage and administration. For example, administration of one 500 mg capsule provides the preferred minimum dosage while administration of two such capsules before each meal provides the preferred maximum daily dosage.
The following description indicates a preferred formulation and its method of preparation. It is to be understood that this description is given by way of example only and is not to be taken as limiting the scope of the present invention.
The indicated quantities of the foilowing ingredients were used to form a batch of material from which at least 20,000 capsules each containing 500 mg of Xanthan Gum was prepared. The formulation is designed to provide a composition which not only acts as an appetite suppressant but also as a vitamin supplement and used natural ingreidents only.
Ingredients Amount (g) Safflower Oil 4,430.00 Wax mixture 600.00 Lecithin 300.00 Labrafil M 4,196.40 Cetomacrogol 1000 101.20 Vitamin A Palmitate 1 miu/g 88.00 Calciferol Solution 2 miu/g 6.00 dl Alpha Tocopheryl Acetate 600.00 Thiamine Mononitrate 50.00 Riboflavine 26.40 Pyridoxine HCI 22.00 Niacinamide 220.00 Ascorbic Acid 750.00 Xanthan Gum * 10,000.00 Chlorophyll C.C. 10.00 * The Xanthan gum used was that sold under the trade mark KELTROL manufactured by Kelco Company of San Diego, California, United States of America.
The safflower oil vehicle, wax mixture thickening agent and the lecithin and cetomacrogol 1000 emulsifiers were mixed and warmed to 60"C. The warmed mixture was stirred until an homogenous solution was obtained, the labrifil M emulsifier was added with stirring and the mixture cooled to 30"C. The balance of the ingredients was added in the order given in the above tabie, the mixture being stirred during the addition of the balance of the ingredients and until uniform. The uniform mixture was then dearated and a sample taken for testing purposes. The mixture was then restirred avoiding aeration and encapsulated in gelatin capsules containing 500 mg of Xanthan Gum per capsule.

Claims (17)

1. An appetite suppressant composition comprising an orally acceptable xanthan gum in associated with an orally acceptable carrier or diluent.
2. An appetite suppressant composition as claimed in claim 1 in the form of granules.
3. An appetite suppressant composition as claimed in claim 1 in dosage unit form.
4. An appetite suppressant composition as claimed in claim 3 containing from 100 mg to 3 mg of xanthan gum.
5. An appetite suppressant composition as claimed in claim 4 containing from 500 mg to 3 g of xanthan gum.
6. An appetite suppressant composition as claimed in claim 4 containing about 500 mg of xanthan gum.
7. An appetite suppressant composition as claimed in any one of claims 3-6 in tablet form.
8. An appetite suppressant composition as claimed in any one of claims 3-6 in the form of a wafer or biscuit.
9. An appetite suppressant composition as claimed in any one of claims 3-6 comprising a solution or suspension of xanthan gum contained in a gelatine capsule.
10. An appetite suppressant composition as claimed in any one of claims 3-9 also containing one Dr more vitamins as dietary supplements.
11. An appetite suppressant composition as claimed in claim 1 substantially as hereinbefore described with reference to the Examples.
12. A non-therapeutic method of suppressing the appetite of a human subject which comprises administering to the subject at least 100 mg of - xanthan gum per day.
13. A method as claimed in claim 12 in which the xanthan gum is administered to the subject in an amount of from 100 mg to 3 g per day.
14. A method as claimed in claim 13 in which the xanthan gum is administered to the subject in an amount of from 500 mg to 3 g per day.
15. A method as claimed in any one of claims 12-14 in which the xanthan gum is administered to the subject in the form of an appetite suppressant composition as claimed in any one of claims 1-11.
16. An orally acceptable therapeutic composition for suppressing the appetite of human beings comprising xanthan gum.
17. Acomposition as claimed in claim 16 having the features as defined in any one of claims 1-11.
GB7922348A 1978-06-27 1979-06-27 Compositions containing xanthan gum Expired GB2029216B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AU488078 1978-06-27

Publications (2)

Publication Number Publication Date
GB2029216A true GB2029216A (en) 1980-03-19
GB2029216B GB2029216B (en) 1982-12-01

Family

ID=3695327

Family Applications (1)

Application Number Title Priority Date Filing Date
GB7922348A Expired GB2029216B (en) 1978-06-27 1979-06-27 Compositions containing xanthan gum

Country Status (2)

Country Link
AU (1) AU526184B2 (en)
GB (1) GB2029216B (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0215635A2 (en) * 1985-09-11 1987-03-25 Lilly Industries Limited Chewable capsules
JP2007508329A (en) * 2003-10-17 2007-04-05 ダイエット・フォーミュレイションズ・リミテッド Weight loss supplements
US20150374014A1 (en) * 2013-03-15 2015-12-31 Mars, Incorporated Aerated pet treat

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0215635A2 (en) * 1985-09-11 1987-03-25 Lilly Industries Limited Chewable capsules
EP0215635A3 (en) * 1985-09-11 1988-01-13 Lilly Industries Limited Chewable capsules
JP2007508329A (en) * 2003-10-17 2007-04-05 ダイエット・フォーミュレイションズ・リミテッド Weight loss supplements
US20150374014A1 (en) * 2013-03-15 2015-12-31 Mars, Incorporated Aerated pet treat

Also Published As

Publication number Publication date
AU526184B2 (en) 1982-12-23
GB2029216B (en) 1982-12-01
AU4841679A (en) 1980-01-03

Similar Documents

Publication Publication Date Title
CA2079325C (en) Nutritional supplement containing vitamin e
US4751241A (en) Pharmaceutical composition of cyclandelate having a high degree of bioavailability
US4965252A (en) Cholesterol-lowering combination compositions of guar gum and niacin
AU633959B2 (en) Pharmaceutical formulations
EA006141B1 (en) Preparation of vitamin emulsions and concentrates thereof
EP0211946B1 (en) Controlled release potassium chloride
JPH0474339B2 (en)
JP3285410B2 (en) Oral pharmaceutical composition containing anthocyanosides
EP0152292A2 (en) Acetaminophen gelatin capsules
JP3073224B2 (en) Food or pharmaceutical composition for improving brain function and method for producing the same
JPS6230965B2 (en)
CA2143070C (en) Oral controlled release liquid suspension pharmaceutical formulation
JPH08503964A (en) Dietary hypocholesterolemic composition
KR970000043B1 (en) Nutritional supplement
GB2029216A (en) Compositions containing xanthan gum
EA004808B1 (en) Bioavailable dosage form of isotretinoin
US3144387A (en) Anti-inflammatory compositions
JPH10139673A (en) Pharmaceutical preparation
JP2769587B2 (en) Powder nutrition composition
EP0073006B1 (en) Medicinal composition and method of making same
US3843786A (en) Method of controlling human appetite
JPS63246333A (en) Intestine-activating type soft capsule preparation mainly containing components resisting pantothenic acid deficiency
JPS6277320A (en) L-ascorbic acid pharmaceutical and production thereof
CN101167721A (en) Compound preparation containing orlistat
JPH0687750A (en) Medicine composition

Legal Events

Date Code Title Description
PCNP Patent ceased through non-payment of renewal fee